As of 2024-07-27, the Relative Valuation of ACADIA Pharmaceuticals Inc (ACAD) is (0.33) USD. This relative valuation is based on P/E multiples. With the latest stock price at 19.14 USD, the upside of ACADIA Pharmaceuticals Inc based on Relative Valuation is -101.7%.
The range of the Relative Valuation is (0.33) - (0.34) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.0x - 32.9x | 31.8x |
| Forward P/E multiples | 30.3x - 31.8x | 31.2x |
| Fair Price | (0.33) - (0.34) | (0.33) |
| Upside | -101.7% - -101.8% | -101.7% |
| Date | P/E |
| 2024-07-26 | -1,809.10 |
| 2024-07-25 | -1,753.34 |
| 2024-07-24 | -1,746.72 |
| 2024-07-23 | -1,719.31 |
| 2024-07-22 | -1,713.64 |
| 2024-07-19 | -1,677.72 |
| 2024-07-18 | -1,701.35 |
| 2024-07-17 | -1,734.43 |
| 2024-07-16 | -1,759.95 |
| 2024-07-15 | -1,704.19 |
| 2024-07-12 | -1,679.61 |
| 2024-07-11 | -1,668.27 |
| 2024-07-10 | -1,617.23 |
| 2024-07-09 | -1,619.12 |
| 2024-07-08 | -1,542.56 |
| 2024-07-05 | -1,524.60 |
| 2024-07-03 | -1,473.56 |
| 2024-07-02 | -1,497.19 |
| 2024-07-01 | -1,516.09 |
| 2024-06-28 | -1,535.94 |
| 2024-06-27 | -1,547.28 |
| 2024-06-26 | -1,465.05 |
| 2024-06-25 | -1,474.50 |
| 2024-06-24 | -1,500.97 |
| 2024-06-21 | -1,446.15 |
| 2024-06-20 | -1,394.16 |
| 2024-06-18 | -1,405.50 |
| 2024-06-17 | -1,402.67 |
| 2024-06-14 | -1,409.29 |
| 2024-06-13 | -1,426.30 |
| 2024-06-12 | -1,452.76 |
| 2024-06-11 | -1,420.63 |
| 2024-06-10 | -1,406.45 |
| 2024-06-07 | -1,407.39 |
| 2024-06-06 | -1,446.15 |
| 2024-06-05 | -1,448.04 |
| 2024-06-04 | -1,460.33 |
| 2024-06-03 | -1,444.26 |
| 2024-05-31 | -1,427.24 |
| 2024-05-30 | -1,417.79 |
| 2024-05-29 | -1,381.87 |
| 2024-05-28 | -1,426.30 |
| 2024-05-24 | -1,436.70 |
| 2024-05-23 | -1,468.83 |
| 2024-05-22 | -1,495.30 |
| 2024-05-21 | -1,443.31 |
| 2024-05-20 | -1,427.24 |
| 2024-05-17 | -1,397.94 |
| 2024-05-16 | -1,403.61 |
| 2024-05-15 | -1,429.13 |